Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
Now approved for both acute and chronic HCV in adults and children aged 3 and above
The company has posted net profit of Rs. 1,414.44 crores for the Financial Year ended March 31, 2025
Mistry is a seasoned finance professional having an extensive work experience spanning more than 25 years
Anushree has been with Abbott since 2021 and currently serving as Head of Strategy and Portfolio
Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System offers a new potential treatment by using sound pressure waves to treat arterial calcium blockages
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
Prithwish has close to 28 years of experience in a Commercial role
Subscribe To Our Newsletter & Stay Updated
